絞り込み

16646

広告

東北電力 女川原発2号機 地元自治体が再稼働をどう判断か注目 (NHK)

26日、原子力規制委員会の審査に合格した宮城県にある女川原子力発電所2号機について国と東北電力は、再稼働に必要な自治体の同意に向けた手続きを進めることになり今後...

  1. 無観客ライブを無料配信 会場費などはファ...
  2. 突然の異常行動を伴う頭痛、疑うべき疾患は...
  3. COVID-19の拡大で重み増す保健所長...
  4. SARS-CoV-2が眼から感染する可能...

ニュース一覧

Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.

著者 Hoylman E , Brown A , Perissinotti AJ , Marini BL , Pianko M , Ye JC , Campagnaro E , Nachar VR
Leuk Lymphoma.2019 Nov 18 ; ():1-8.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (48view , 0users)

Full Text Sources

Daratumumab and elotuzumab have demonstrated improvements in overall response rates (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM). There is a lack of comparative clinical trials and an even larger lack of consensus on the optimal integration of these novel agents into the treatment paradigm. Clinical outcomes were compared retrospectively in 37 patients who received daratumumab before elotuzumab (dara-first,  = 23) and patients who received elotuzumab before daratumumab (elo-first,  = 14). ORR to the first monoclonal antibody was not different (dara-first 56.5% vs. elo-first 64.3%,  = .641). ORR to the second antibody differed when daratumumab was given second compared to when elotuzumab was given second (64.3% vs. 34.8%, respectively;  = .081). Cumulative PFS for elo-first was significantly longer than dara-first (22.67 months vs. 10.5 months, respectively;  = .001). Response rates to daratumumab may be preserved irrespective of sequence. However, response rates to elotuzumab may diminish with prior daratumumab exposure.
PMID: 31739729 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード